Abstract: This invention relates to compositions/devices and methods for treating diseases of the oral cavity in humans and lower animals using polylactide/glycolide compositions/devices also containing triacetin for releasing drugs in the oral cavity.

Abstract: Omega-3, 20-22 carbon atom, hexa- or penta-unsaturated fatty acids are used in the treatment of periodontal disease.

Abstract: A purified, characterized surface protein from Bacteroides loeschei is an adhesin which is useful in inhibiting plaque formation. The adhesin is also useful in a diagnostic assay for gingivitis, a diagnostic indicator for changes in the surface components of certain human tissues, and as a binding agent to purify polysaccharides.

Abstract: A method of reducing bone loss and promoting bone regrowth, once loss has occurred, particularly alveolar bone loss associated wtih periodontal disease, and a composition useful in the method. The method comprises applying to buccal membranes a therapeutically effective quantity of at least one S enantiomer, generally an S(+) enantiomer, of a nonsteroidal anti-inflammatory drug, such as S(+) flurbiprofen or S(+) ketoprofen. The composition is a formulation which is a toothpaste or which is a mouthwash.

Abstract: A method of treatment for periodontitis comprises the topical or systemic administration of a pharmaceutical composition containing at least one retinoid compound other than Vitamin A. Preferred retinoids include Vitamin A aldehyde, Vitamin A acid, Vitamin A esters, isotretinoin, etretinate and acitretin.

Abstract: Disclosed herein are analogues of the luteinizing hormone-releasing hormone (LH-RH), which are potent antagonists of LH-RH. These peptides inhibit the release of gonadotropins from the pituitary in mammals, including humans and possess antitumor activity.Formula I represents peptides which are within the scope of this invention:X--R.sup.1 --R.sup.2 --R.sup.3 --Ser--R.sup.5 --R.sup.6 (AY.sub.2)--Leu--Arg--Pro--D--Ala--NH.sub.2 Iand the pharmaceutically acceptable salts thereof, whereinR.sup.1 is D-Phe, D-Phe(4Cl), D-Nal(1) or D-Nal(2),R.sup.2 is D-Phe or D-Phe(4HI),R.sup.3 is D-Trp, D-Phe, D-Phe(4HI), D-Nal(1), D-Nal(2) or D-Pal(3),R.sup.5 is Tyr or Arg,R.sup.6 is D-Lys or D-Orn,HI is fluoro, chloro or bromoX is a lower alkanoyl group of 2-5 carbon atoms,A is a diaminoacyl residue having the formula ##STR1## where m is 0 or 1,n is 0 or 1,Y is Y.sup.1 or Y.sup.2, whereinY.sup.

Abstract: An oral composition, such as a paste or gel dentifrice or a liquid mouthwash, containing a substantially water insoluble non-cationic antibacterial agent, such as triclosan, which, when used to clean the teeth or rinse the mouth, acts to decrease plaque on the teeth, is packaged in a dispensing container which includes a solid polymeric material, such as polyfluoroethylene, which is compatible with the antibacterial agent so that excessive loss of anti-plaque activity of such agent on storage is avoided. Alternatively, various other polymers may be employed as container parts, which normally would cause excessive losses of anti-plaque action of the antibacterial agent in the composition, but such action is countered by the presence of a stabilizer, such as a terpene, e.g., limonene, in the oral composition formula.

Abstract: The invention relates to a liquid methacrylic acid copolymer composition that contains a release adjusting agent and a pharmacological agent. The composition forms a solid film upon drying, and is capable of accomplishing the sustained release of the pharmacological agent such as to permit its use in the treatment or prevention of dental or dermatological conditions.

Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.

Abstract: The invention relates to an oral composition for the treatment and prevention of dental hypersensitivity comprising an anti-hypersensitivity agent embedded in a sustained release carrier such as a cellulosic or hydrophobic polymer, and a method for the use of said composition in treating and preventing dental hypersensitivity. The invention also provides for the supplementation of said oral composition with an adhesive and a plasticizer to increase the effectiveness of the anti-hypersensitivity agent.

Abstract: An oral composition, such as a paste or gel dentifrice or a liquid mouthwash, containing a substantially water insoluble non-cationic antibacterial agent, such as triclosan, which, when used to clean the teeth or rinse the mouth, acts to decrease plaque on the teeth, is packaged in a dispensing container or bottle which includes a solid polymeric material, such as polyfluoroethylene, which is compatible with the antibacterial agent so that excessive loss of anti-plaque acitivity of such agent on storage is avoided. Alternatively, various other polymers may be employed as container parts, which normally would cause excessive losses of anti-plaque action of the antibacterial agent in the composition but such action is countered by the presence of a stabilizer, such as a terpene, e.g., limonene, in the oral composition formula. Also described is a method for inhibiting development of plaque on teeth.

Abstract: Oral cavity and dental products are prepared by microemulsifying an adsorptive oil in an aqueous medium to produce uniform submicron sized droplets. The products avoid the generally unaesthetic, oily, and unpleasant taste problems of previous similar products.

Abstract: The invention relates to an oral composition for prevention of mycotic infections of the oral cavity comprising an antifungal compound embedded in a sustained release carrier such as a cellulosic polymer or a hydrophobic polymer, and a method for use of said composition in preventing microfungal infections in the oral cavity. The invention also provides for the supplementation of said oral composition with an adhesive and a plasticizer to increase antifungal effectiveness.

Abstract: Methods are provided of preventing and treating chemotherapy or radiotherapy induced oral mucositis in a mammal by administering an effective dose of a growth factor, such as TGF-.alpha.. The growth factor may be used alone or in combination with other growth factors. Typically the effective dose is within the range of about 0.01-100 .mu.g/dose, administered 2-4 times daily.

Abstract: A dental plaque-degrading composition containing endodextranase produced by Arthrobacter globiformis W31 exhibiting high degradation efficacy to insoluble glucan produced by Streptococcus mutans IFO 13955, the dental plaque-degrading composition additionally containing .alpha.-amylase of various origins. These compositions are useful for preventing the settlement of Streptococcus mutans in the oral cavity and the formation of new dental plaque and for preventing the dental caries, and provided in the form of dentifrices, denture detergents, troches, mouth washes, chewing gums or candies.

Abstract: This invention relates to compositions/devices and methods for treating diseases of the oral cavity in humans and lower animals using polypropenoic acid compositions/devices for releasing drugs in the oral cavity.

Abstract: An abrasive free hydrogen peroxide tooth whitening dentifrice composition comprises a blend of corn starch, sorbitol, hydrogen peroxide, carbomer 940, flavor, sodium lauryl sulfate, sodium saccharin, potassium sorbate, and sodium benzoate in an aqueous base.

Abstract: This invention relates to the use of certain derivatives of 5-hydroxy and 5-methoxy 2-aminopyrimidines of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, wherein R.sup.1 is H or CH.sub.3 ; R.sup.2 is (C.sub.3 -C.sub.15) straight chain alkyl or (C.sub.7 -C.sub.20)phenylalkyl which may be substituted in the phenyl by one or two fluoro or chloro substituents; and R.sup.3 is H or CH.sub.3 to inhibit interleukin-1 production in a mammal. This invention also relates to the use of such compounds for treating interleukin-1 mediated disorders and dysfunctions such as bone and connective tissue metabolism disorders and immune dysfunction in a mammal. The methods of this invention comprise administering an interleukin-1 production inhibiting amount of the compounds and salts of this invention to such a mammal.

Abstract: This invention relates to a method of treating the oral cavity with ingestible, non-foaming, non aqueous, liquid and semi-solid oral hygiene preparations containing: a nonionic surfactant, a coating substance insoluble in said surfactant and a microbially active form of stannous fluoride.

Abstract: Absorption of Tissue Respiration Factor (TRF) into the gingival tissues is materially enhanced when it is formulated as a non-astringent hydrophilic pharmaceutical composition containing penetration promoting substances which are both hydrophilic and lipophilic. Additionally, a highly efficient means for effecting absorption of TRF into the gingival tissues is to utilize liposomes as carriers for the TRF in a non-astringent pharmaceutical composition.

Abstract: This invention describes ingestible, non-foaming, non-aqueous liquid and semi-solid oral hygiene preparations containing: a nonionic surfactant, a coating substance insoluble in said surfactant and a microbially active form of stannous fluoride.

Abstract: Process for preparing raw hide containing at least one inorganic pyrophosphate compound, comprising: (a) subjecting raw hide to a solution containing at least one inorganic pyrophosphate compound; and (b) drying the raw hide containing the inorganic pyrophosphate salt. The raw hide containing the inorganic pyrophosphate is chewed and/or eaten by dogs, with the result that tartar accumulation on their teeth is reduced or prevented.

Abstract: Synergistic compositions comprising an antioxidant and an arylpropionic, non-steroidal anti-imflammatory drug used to treat certain diseases are disclosed. The compositions inhibit production of arachidonic acid cascade end-products which have been implicated as causes of tissue-destruction in periodontal disease. The compositions are administered in combination with a carrier, which may be a mucosal-tenacious polymer selected from the groups of semi-solid pastes, gels, ointments, liquids or films.

Abstract: The present invention relates to oral compositions, such as dentifrices, toothpastes and mouthwashes, which provide an anticalculus benefit. These compositions comprise a safe and effective amount of an anticalculus agent which is a polyepoxysuccinic acid, or its pharmaceutically-acceptable salts, along with a pharmaceutically-acceptable carrier. The present invention also relates to a method for inhibiting or reducing the development of dental calculus by contacting the oral cavity with a safe and effective amount of an anticalculus agent which is a polyepoxysuccinic acid, or its pharmaceutically-acceptable salt.

Abstract: This invention relates to pharmaceutical compositions comprising anaerobe-selective antibacterial agents which are substituted or unsubstituted, 1,12-dodecanedioic peroxy acids, or their pharmaceutically-acceptable salts or esters. The pharmaceutical compositions of the present invention are especially suitable for oral administration in the form of mouth rinses and toothpastes. These anaerobe-selective antibacterial compositions are useful for treating or preventing anaerobic bacterial infections, especially diseases of the oral cavity, in humans or lower animals.The present invention further relates to a method for treating or preventing anaerobic bacterial infections such as acne, and especially diseases of the oral cavity such as gingivitis and periodontal disease, in humans or lower animals.

Abstract: Drug delivery devices and techniques are described for use in treatment of periodontal disease and the like. The delivery device includes benzo (c) phenanthridine alkaloid in a bioerodable and biocompatible material. The alkaloid is slowly released from the bioerodable material in the oral cavity. The bioerodable material may be polymeric and may be natural or synthetic. The delivery device may be inserted subgingivally (e.g., in a periodontal pocket) where the alkaloid is released slowly over a period of days.

Abstract: A pharmaceutical combination of Metronidazole and Amoxicillin for the treatment of periodontitis. Conventional therapeutic doses of both the Metronidazole and Amoxicillin given as a combination therapy has been unexpectedly found to effectively treat periodontitis.

Abstract: Oral compositions containing a cationic antimicrobial agent and benzoic acid and phthalic acid or salts of these acids, which compositions are effective against plaque and gingivitis, are disclosed. Also disclosed are methods for reducing plaque and gingivitis.

Abstract: Adhesion of bacteria in the buccal cavity which are responsible for the formation of dental plaque and caries is inhibited by kappa-caseino-glycopeptide compounds and desialylated derivaties thereof contained in compositions having a form suitable for being empolyed for treating the bacteria in the buccal cavity.

Abstract: Kappa-caseino-glycopeptide compounds and desialylated derivatives thereof and compositions containing the same are employed for treating bacteria in the buccal cavity which are responsible for the formation of dental plaque and caries.

Abstract: The invention relates to an oral hygiene composition for treating or preventing anaerobe infections in humans and lower animals.

Abstract: Methods of retarding and reversing periodontoclasia and gingivitis and disorders of human gingiva over 60 years of age comprise topically applying to human gingiva retinoic acid in an amount effective to retard and reverse periodontoclasia and gingivitis where said amount is insufficient to be excessively irritating. An emollient vehicle, a toothpaste and a liquid rinse facilitating the same methods are included.

Abstract: A pharmaceutical composition for treating periodontal diseases which comprises one or more of therapeutically active ingredients admixed with a polymer capable of dissolving in an aqueous medium of pH 4.0 or higher.

Abstract: Etofenamate is used for the preparation of compositions useful in the treatment of bacterial, viral or fungicidal inflammations in the region of the oral cavity.

Abstract: An oral hygiene composition in the form of a dentifrice or a mouthwash, comprising: (a) from 0.01 to 2% by weight of the composition of an antibacterial compound of formula (I): ##STR1## in which R.sup.1 is oxygen, sulphur or an alkylene group of from 1 to 6 carbon atoms, each of R.sub.2 to R.sub.6 and R.sup.2 ' to R.sup.6 ' is hydrogen, hydroxyl or halogen; (b) from 0 to 90% by weight of a dentally acceptable abrasive, (c) from 0.1% to 15% by weight of a dialkali or tetra-alkali metal pyrophosphate salt or a mixture thereof and (d) water.

Abstract: A tooth and gum paste in the form of a staple composition for controlling peridontal disease, reduction of plaque and oral oders in which one or more of the ingredients is microencapsulated within the composition.

Abstract: An anticariogenic or antiperiodontitic agent containing, as an active component, yeast cells and/or water-soluble extracts of yeasts having antibacterial activity against Streptococcus mutans or Bacteroides gingivalis. This anticariogenic or antiperiodontitic agent has strong inhibitory effects on the growth of Streptococcus mutans causing dental caries and Bacteroids gingivalis causing periodontitis and has neither influence on intestinal microflora nor any side-effects when orally administered.

Abstract: A muscosal delivery system is provided for use in treating periodontal disease. The system is composed of a chemotherapeutic agent dissolved in a skin-penetration enhancer. The solution of chemotherapeutic agent and skin-penetration enhancer is placed into the periodontal pocket where the agent is transported into the surrounding gingival tissue by means of the penetration enhancer.

Abstract: A method for treating or preventing periodontal disease which comprises administering ofloxacin or salts thereof locally to periodontal tissue are disclosed. The method is excellent on the treatment of periodontal disease in small dose without disturbance of bacterial flora.

Abstract: Oral hygiene methods and compositions for reducing plaque and for the prevention and treatment of periodontal diseases of bacterial etiology by significantly reducing bacterial activity in the oral cavity through the inclusion of at least about 0.03% by weight of an extract of the perennial herb periwinkle in the compositions and applying the compositions to the oral cavity.

Abstract: 2-(2,6-Dichloro-3-methylphenylamino)benzoic acid and its physiologically acceptable salts are effective in inhibiting the conversion of gingivitis to periodontitis and thus useful in treating destructive periodontal disease. The therapeutic agent can be applied directly to the gingival tissue in a topically administerable pharmaceutical composition or can be introduced and released in the buccal cavity for contact with the gingival tissue through the fluid motion present in the mouth.

Abstract: A pharmaceutical composition for treating periodontal diseases which comprises one or more of therapeutically active ingredients dispersed in a carrier, characterized in that said carrier consists of(A) water soluble polymer, and(B) polymeric particles having a limited solubility in water,said particles being dispersed in said water soluble polymer.

Abstract: An oral composition for preventing periodontal diseases through suppression of the colonization of causative bacteria of periodontal diseases comprises an antibody obtained by immunizing a mammal with at least one antigen selected from the group consisting of periodontal causative bacteria, their pilus and capsule fractions, and aluminum hydroxide for stabilizing said antibody.

Abstract: A pharmaceutical composition useful for treatment of periodontal diseases which comprises one or more active ingredients effective for the treatment of periodontal diseases, characterized in that said active ingredient or ingredients are dispersed in collagen.

Abstract: A composition for cleaning the gums comprising silica, water and a detergent, said composition having a RDA of less than 20.

Abstract: A chewing material or items constructed of latex material. In one embodiment of the invention, the latex chewing material is constructed to simulate the size and shape of a stick of conventional chewing gum. The latex material will not deteriorate when being chewed and while not intended to be ingested, it is constructed of non-toxic material and is not harmful if swallowed. The latex chewing material will not stick to any surface or any other item. The material is not water soluble and is sugar free and salt free. Use of the latex chewing material or item will assist in keeping the teeth clean, promote healthy conditions of the teeth and gum by massaging the gums and providing exercise normally associated with mastication. In addition, the use of the latex chewing material will enhance the overall health and hygiene of the oral cavity by stimulating saliva secretions thereby decreasing the potential for bad breath.

Abstract: A composition for treating dental infections, e.g. dental caries caused by Strep. mutans, comprises a varnish containing a dentally acceptable antimicrobial agent such as chlorhexidine acetate and benzoin gum in an orally acceptable liquid. The composition can be painted on teeth, allowed to dry thereon to give a transparent, translucent or tooth colored film which is effectively invisible but provides sustained release of the antimicrobial agent to the site of infection over a period of at least four days. The film can be removed at will, e.g. by application of the liquid varnish base.To sustain further the antimicrobial agent in situ and hinder its egress into the oral cavity, a sealing composition may be applied over the varnish layer. The sealing composition is preferably solvated polyurethane which cures by evaporation of solvent.

Abstract: A composition for preparing a medicament for topical treatment of paradentium diseases, said composition comprising the ammonium salt of sulfoichthyolic acid, zinc oxide, titanium dioxide and fluid extract of Hamamelis in a pharmaceutically acceptable carrier. Said composition is useful especially for treatment of gingivitis and alveolar pyorrhea.

Abstract: Oral hygiene methods for reducing plaque and for the treatment of periodontal diseases of bacterial etiology by significantly reducing bacterial activity in the oral cavity through the inclusion of about 0.03% to at least about 10% by weight of a dried methanol extract of the perennial herb periwinkle in compositions and applying the compositions to the oral cavity.

Abstract: The disclosed compositions for periodontal use are characterized by inclusion of superoxide dismutase, as an active ingredient, in combination with an orally acceptable carrier. Periodontal diseases, in particular alveolar pyorrhea, may be treated and/or prevented by application of superoxide dismutase to oral cavity tissue.